If you or someone you love has been harmed by Phenylpropanolamine (PPA), you may be entitled to compensation. PPA Phenylpropanolamine is an ingredient in many over-the-counter (OTC) and prescription diet drugs, as well as nasal decongestants and cough medicine. PPA has been linked to dangerous side effects such as hemorrhagic strokes that can afflict users within three days of taking the medication.
Attorneys Trial Group knows the dangers of PPA and other unsafe drugs. Since 1988, Florida’s personal injury victims have turned to our attorneys for help in personal injury and dangerous drug cases, as well as wrongful death, motor vehicle accidents (automobile, truck, motorcycle), defective products, medical malpractice, nursing home abuse, insurance contract disputes and theme park negligence claims. We have helped Floridians receive hundreds of millions of dollars in favorable verdicts and settlements. Our team of professionals includes nurses, doctors, engineers and other experts who are supported by leading technology that enables us to keep in touch with the legal community, legislative developments and our clients. If you or someone you know has suffered adverse effects from the use of PPA, you’ll need an attorney with the experience and resources to help you stand up to the giant drug manufacturers and insurance companies. We encourage you to contact our office today to discuss your situation. The consultation is complimentary.
PPA has been available for at least 53 years, with as many as 400 over-the-counter (OTC) products and prescription drugs containing PPA as an active ingredient. Phenylpropanolamine is used in OTC drugs as a nasal decongestant and in weight control products to regulate appetite. You may recognize popular name brands that contain Phenylpropanolamine including Dexatrim, Acutrim, Alka-Seltzer, Bayer Cold, Robitussin, Comtrex and Tavist D. If you are a consumer, check all of the ingredients list on the package to ensure you know exactly what you are taking.
In 2000, the Food and Drug Administration (FDA) officially acted to have Phenylpropanolamine removed from the market as a result of a Yale study that concluded that women taking PPA-related products were at a higher risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain). While the study found that women are especially vulnerable to hemorrhagic stroke, the FDA warned that men may also in danger. The FDA requested that companies that market drugs containing PPA voluntarily discontinue marketing the pharmaceutical and advised consumers to use an alternative drug. Alternatives for decongestion include long acting nasal decongestant sprays that contain oxymetolazine. In fact, it has been found that using nasal sprays that contain oxymetolazine may be more effect while producing less side effects than PPA products. For those looking for help losing weight, all effective appetite suppressants are stimulants that can raise blood pressure. While PPA diet products may produce short term weight loss, the only successful diet for the long term is eating sensibly and exercising.
A drug maker is held liable if they fail to manufacture a safe product or are negligent in their responsibility to design, manufacture, inspect, and label a product appropriately. Proving negligence in pharmaceutical and product liability claims is complicated. At Martinez, Manglardi, & , we speak for the victim. We have the experience and resources to take on giant pharmaceutical companies and insurance bureaucracies. Over $100 million in verdicts and settlements demonstrates our ability to effectively represent clients in a wide range of cases. Contact Attorneys Trial Group today to learn more about how we may be able to help you receive compensation for pain, lost wages, medical bills and other damages. We offer free consultations in your home, at the hospital or in our offices. There are no fees or costs unless you win. Contact us today in Orlando at (407) 381-4123, or in Kissimmee, (407) 846-2240 or via our online contact form.
Phenylpropanolamine PPA in the News
Drug Enforcement Administration’s (DEA) Chemical Industry Conference 2004 (Sept. 14, 2004)
Of particular interest was the proposed rule on security requirements for handlers of pseudoephedrine, ephedrine, and phenylpropanolamine. DEA is proposing that the security required to handle ephedrine, pseudoephedrine, and phenylpropanolamine be enhanced to the level that is required for Schedule III – V controlled substances.